Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions
Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions
Overview
Switzerland isolator systems maker's H1 net sales rose 22% yr/yr, driven by robust demand
Company returned to profit in H1, with net result of CHF 5.4 mln after prior-year loss
Profitability improved as project delays eased and Services & Consumables segment grew strongly
Outlook
SKAN confirms 2026 guidance: net sales to grow in high-teens percent range
Company expects 2026 EBITDA margin between 13% and 15%
SKAN sees robust demand but notes customers are prioritizing investments more selectively
Result Drivers
ACQUISITIONS - Consolidated acquisitions during the reporting period contributed to net sales growth
PROJECT DELAYS EASED - Profitability improved as prior-year project delays did not recur to the same extent and more projects were in high-value-added phases
SERVICES & CONSUMABLES SEGMENT - Strong growth in Services & Consumables, including acquisitions, boosted net sales and profitability
Company press release: ID:nEQ5jlbwDa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Sales |
| CHF 164.48 mln |
|
H1 EPS |
| CHF 0.21 |
|
H1 Net Income |
| CHF 5.45 mln |
|
H1 Cash Flow from Operating Activities |
| CHF 16.32 mln |
|
H1 EBIT |
| CHF 8.67 mln |
|
H1 EBITDA |
| CHF 15.28 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for SKAN Group AG is CHF62.50, about 8.3% above its August 17 closing price of CHF57.70
The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 30 three months ago
Reuters Recommended Reads
Aug 17 - Switzerland's Trifork Q2 revenue rises on Products segment growth, reiterates 2026 outlook
Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Aug 17 - Switzerland's HIAG Immobilien H1 net income jumps 90% on Chama condominium sales, revaluation gains
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on SKAN AG
See all newsEurope Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions
Brief: SKAN H1 Sales CHF 164.484 Million
Europe Research Roundup: DSV, Montea, Sodexo